

Imatinib Drug Market 2026

<https://marketpublishers.com/r/I338A800F974EN.html>

Date: February 2025

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: I338A800F974EN

Abstracts

The Imatinib Drug Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Imatinib Drug Market.

This report delivers a comprehensive overview of the Imatinib Drug Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Imatinib Drug Market. The Imatinib Drug Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for —.

Imatinib Drug Market Scope:

By Application

Chronic Eosinophilic Leukemia

Philadelphia Positive Chronic Myeloid Leukemia

Hyper-Eosinophilic Syndrome (HES)

Myelodysplastic Syndrome (MDS)

Myeloproliferative Diseases (MPD)

Gastrointestinal Stromal Tumors (GIST)

Others

By Drug Formulation

Capsules

Tablets

By End Use

Hospital Pharmacies

Ambulatory Surgical Centers

Clinics

Other

Key Players

Sun Pharmaceutical Industries Ltd.

Novartis AG

Dr. Reddy's Laboratories Ltd

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Cipla Inc

Apotex Inc,

Sanofi S.A.

Actavis Generics

Glenmark Pharmaceuticals Ltd.(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Imatinib Drug Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Imatinib Drug Market. The Imatinib Drug Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Application
- 3.2. Market snippet by Drug Formulation
- 3.3. Market snippet by End Use
- 3.4. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increase in demand of target drug therapy
 - 4.1.1.2. Prevalence of cancer
 - 4.1.2. Restraints:
 - 4.1.2.1. Presence of substitute drug
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Unmet Needs

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market

- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY APPLICATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
 - 7.1.2. Market Attractiveness Index, By Application Segment
- 7.2. Chronic Eosinophilic Leukemia *
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 7.3. Philadelphia Positive Chronic Myeloid Leukemia
- 7.4. Hyper-Eosinophilic Syndrome (HES)
- 7.5. Myelodysplastic Syndrome (MDS)
- 7.6. Myeloproliferative Diseases (MPD)
- 7.7. Gastrointestinal Stromal Tumors (GIST)
- 7.8. Others

8. BY DRUG FORMULATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
 - 8.1.2. Market Attractiveness Index, By Drug Formulation
- 8.2. Capsules *
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 8.3. Tablets

9. BY END USE

- 9.1. Introduction

- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use Segment
- 9.1.2. Market Attractiveness Index, By End Use Segment
- 9.2. Hospital Pharmacies *
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 9.3. Ambulatory Surgical Centers
- 9.4. Clinics
- 9.5. Other

10. BY REGION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
 - 10.2.1. Introduction
 - 10.2.2. Key Region-Specific Dynamics
 - 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
 - 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
 - 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
 - 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.2.6.1. U.S.
 - 10.2.6.2. Canada
 - 10.2.6.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics
 - 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
 - 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
 - 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
 - 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 10.3.6.1. Germany
 - 10.3.6.2. U.K.
 - 10.3.6.3. France
 - 10.3.6.4. Italy
 - 10.3.6.5. Spain
 - 10.3.6.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation

10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use

10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.4.6.1. Brazil

10.4.6.2. Argentina

10.4.6.3. Rest of South America

10.5. Asia Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation

10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use

10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.5.6.1. China

10.5.6.2. India

10.5.6.3. Japan

10.5.6.4. Australia

10.5.6.5. Rest of Asia Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation

10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use

11. COMPETITIVE LANDSCAPE

11.1. Key Developments and Strategies

11.2. Company Share Analysis

11.3. Product Benchmarking

11.4. List of key companies to watch

11.5. List of the company with disruptive technology

11.6. List of start-up companies

12. COMPANY PROFILES

- 12.1. Sun Pharmaceutical Industries Ltd. *
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio and Description
 - 12.1.3. Key Highlights
 - 12.1.4. Financial Overview
- 12.2. Novartis AG
- 12.3. Dr. Reddy's Laboratories Ltd
- 12.4. Teva Pharmaceutical Industries Ltd.
- 12.5. Mylan N.V.
- 12.6. Cipla Inc
- 12.7. Apotex Inc,
- 12.8. Sanofi S.A.
- 12.9. Actavis Generics
- 12.10. Glenmark Pharmaceuticals Ltd.(*LIST NOT EXHAUSTIVE)

13. DATAM INTELLIGENCE

- 13.1. Appendix
- 13.2. About Us and Services
- 13.3. Contact Us

I would like to order

Product name: Imatinib Drug Market 2026

Product link: <https://marketpublishers.com/r/I338A800F974EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I338A800F974EN.html>